Pharma Penny Stock Under Rs 30: Board to Meet on June 19 to Consider, Evaluate and Approve Proposal of Raising Further Funds
The stock gave multibagger returns of 292 per cent from its 52-week low of Rs 7.35 per share.
Sudarshan Pharma Industries Limited (SPIL) informed that a meeting of the company's Board of Directors is scheduled for Thursday, June 19, 2025. The board will convene to discuss, evaluate, and potentially approve a proposal to raise further funds. This could involve issuing equity shares or other equity-linked instruments, such as convertible instruments or warrants, pending necessary approvals.
Additionally, the company has been recognised as a One Star Export House by the Directorate General of Foreign Trade, valid from May 8, 2025, to March 31, 2028. This comes after SPIL's recent acquisition of Cibachem General Trading L.L.C., a Dubai-based entity, for Rs 55,00,000. This strategic acquisition of the 300 shares, subject to RBI approval and expected to close by September 30, 2025, aims to expand SPIL's customer base in the Middle East. Cibachem, established in 2013, reported turnovers of AED 4,99,250 in 2024, AED 3,51,050 in 2023, and AED 4,92,588 in 2022.
Sudarshan Pharma Industries Limited (SPIL), established in 2008 and headquartered in Mumbai, is a prominent contract manufacturer of generic formulations. SPIL caters to a wide range of institutions and healthcare organisations operating across diverse segments, including speciality chemicals, intermediates, APIs, pharmaceutical and formulation generics, and bulk supply. Beyond its contract manufacturing services, SPIL has ventured into branded products through its Vimac Healthcare division. A significant portion of its product portfolio, consisting of 56 out of 96 items, is registered under the "R" trademark. Furthermore, SPIL collaborates with renowned Indian companies and institutional clients, offering contract manufacturing services for pharmaceutical formulations and medicines.
DSIJ’s ‘Micro Marvel' service recommends micro-cap stocks with the potential to grow multifold in long run. If this interests you, do download the service details here.
According to the half-yearly results, the net sales increased by 19 per cent to Rs 277 crore and net profit increased by 43 per cent to Rs 7 crore in H2FY25 compared to H2FY24. In its annual results, the net sales increased by 9 per cent to Rs 505 crore and net profit increased by 45 per cent to Rs 16 crore in FY25 compared to FY24. The company has a market cap of Rs 731 crore and has delivered good profit growth of 37 per cent CAGR over the last 5 years. The company is aiming to increase their profit margin when it resells Active Pharmaceutical Ingredients (API) within India. This strategy led to a notable increase in their EBITDA margin in the second half of the financial year 2025 (H2FY25), which resulted in a substantial growth in their Profit After Tax (PAT) for the same period.
The stock’s 52-week high is Rs 53.50 per share while its 52-week low is Rs 7.35 per share. On November 22, 2024, the shares of the company ex-traded sub-division /stock split of the company’s 1 (one) equity share having a face value of R 10 each fully paid-up, into 10 equity shares of the company having a face value of Re 1 each fully paid-up. In March 2025, FIIs bought 1,29,48,000 shares and increased their stake to 18.45 per cent compared to September 2024. The stock gave multibagger returns of 292 per cent from its 52-week low of Rs 7.35 per share.
Disclaimer: The article is for informational purposes only and not investment advice.